Company Profile

PharmaNutra S.p.A. specializes in the research, development and marketing of nutraceutical products. Also, the group develops an activity involving the manufacturing and sales of medical devices and pharmaceuticals. The group's activity is organized around 3 product families:
- food supplements: iron, folic acids, vitamins, omega 3 and microelement-based products sold under SiderAL, Gestalys, Bonecal, Novomega and Dikappa2 brands, intended for the treatment of anemia and food deficit, and the prevention of cardiovascular disorders. Additionally, PharmaNutra offers anti-inflammatory products for joint and musculoskeletal pain relief (Cetilar);
- medical devices, generic drugs and OTC products (Junia Pharma). Moreover, the group markets infant nutritional supplements;
- bioactive ingredients and pharmaceutical active ingredients (Alesco): for the pharmaceutical, agri-food and nutraceutical industries.
Its products are marketed through direct sales (69.5% of net sales), partner distributors (28.1%) and other (2.4%).
Net sales are distributed geographically as follows: Italy (71.6%), Europe (15.3%), Middle East (9.3%), Africa (1.2%), Far East (0.7%) and other (1.9%).


Source: Cofisem - Last Update: 2024-02-18

Key Executives
Chairman and Chief Executive Officer Andrea Lacorte


Source: Cofisem - Last Update: 2024-02-18

Key Figures
Millenium 2022 2021 2020 2019 2018
Net sales 82,724 68,114 56,449 53,624 47,673
Income from ordinary activities 82,724 68,114 56,449 53,624 47,673
Operating income 23,040 18,691 13,216 12,204 11,916
Cost of financial indebtedness net -68 -99 -61 -28 61
Equity-accounted companies contribution to income
Net profit from discontinued activities
Net income 15,048 13,771 14,072 8,454 8,557
Net income (Group share) 15,048 13,771 14,072 8,454 8,557
Fiscal year end 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Length of fiscal year (month) 12 12 12 12 12
Currency & Unit EUR - thousands EUR - thousands EUR - thousands EUR - thousands EUR - thousands
Account Standards

Source: Cofisem - Last Update: 2024-02-18

Shareholder information
Andrea Lacorte 31.38 %
Roberto Lacorte 22.98 %
Beda S.r.l. 10.48 %
Rlh S.r.l. 22.98 %


Source: Cofisem - Last Update: 2024-02-18

Please contact MyQuestion.Italy@euronext.com for Company Profile support.

Quotazioni, Book, Dividendi, Documenti Societari, Corporate Governance, Internal Dealing di Pharmanutra


The Exchange accepts no responsability for the content of the website you are now accessing or for any reliance placed by you or any person on the information contained on it.

By allowing this link the Exchange does not intend in any country, directly or indirectly, to solicit business or offer any securities to any person.


You will be redirected in five seconds.